Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Cash from Operations (2021 - 2025)

Historic Cash from Operations for ARS Pharmaceuticals (SPRY) over the last 5 years, with Q3 2025 value amounting to -$47.0 million.

  • ARS Pharmaceuticals' Cash from Operations fell 22520.22% to -$47.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$85.4 million, marking a year-over-year decrease of 8616.47%. This contributed to the annual value of $13.5 million for FY2024, which is 12285.96% up from last year.
  • Latest data reveals that ARS Pharmaceuticals reported Cash from Operations of -$47.0 million as of Q3 2025, which was down 22520.22% from -$39.6 million recorded in Q2 2025.
  • ARS Pharmaceuticals' 5-year Cash from Operations high stood at $42.0 million for Q4 2024, and its period low was -$47.0 million during Q3 2025.
  • For the 5-year period, ARS Pharmaceuticals' Cash from Operations averaged around -$12.1 million, with its median value being -$12.8 million (2023).
  • As far as peak fluctuations go, ARS Pharmaceuticals' Cash from Operations skyrocketed by 34133.3% in 2024, and later tumbled by 50718.33% in 2025.
  • Quarter analysis of 5 years shows ARS Pharmaceuticals' Cash from Operations stood at $27.9 million in 2021, then tumbled by 173.48% to -$20.5 million in 2022, then rose by 15.09% to -$17.4 million in 2023, then skyrocketed by 341.33% to $42.0 million in 2024, then crashed by 212.01% to -$47.0 million in 2025.
  • Its last three reported values are -$47.0 million in Q3 2025, -$39.6 million for Q2 2025, and -$40.7 million during Q1 2025.